Endocrinology Division, Durand Hospital , Buenos Aires, Argentina .
Thyroid. 2013 Nov;23(11):1479-83. doi: 10.1089/thy.2013.0024. Epub 2013 Sep 20.
Recent guidelines recommend thyrotropin (TSH) target levels of ≤2.5 mIU/L for the first trimester and ≤3 mIU/L for the subsequent trimesters. Euthyroidism should be attained as soon as possible, but there are no precise indications about the initial levothyrorine (LT4) dose. The aim of our study was to determine the appropriate LT4 doses in order to normalize TSH levels in patients with newly discovered subclinical hypothyroidism (SCH) during pregnancy, and to correlate them with basal TSH levels. The adequate LT4 doses for women with SCH were also compared to those required in pregnant women with overt hypothyroidism (OH).
Seventy-seven patients with newly diagnosed hypothyroidism during pregnancy were retrospectively analyzed. Patients were assigned to group 1 (n = 64) with SCH or group 2 (n = 13) with OH. SCH patients were subdivided into two groups: group 1a serum TSH >2.5 (1st trimester) or >3 (2nd or 3rd trimester) to 4.2 mIU/L; and group 1b TSH level > 4.21-10 mIU/L. All patients were treated with LT4 as soon as hypothyroidism was diagnosed. The dose that allowed a TSH of ≤2.5 mIU/L to be reached in the first trimester or one that allowed a TSH of ≤3 mIU/L to be reached during the second and third trimesters was considered the appropriate one.
A significant difference (p < 0.0001) in the appropriate LT4 dose (mean ± SD, μg/kg/day) was observed between group 1 and group 2: 1.31 ± 0.36 versus 2.33 ± 0.59. Patients in group 1a required a significantly lower LT4 dose (p < 0.014) than group1b: 1.20 ± 0.39 versus 1.42 ± 0.31 μg/kg/day. In 57 of the 64 (89.06%) women with SCH and in 10/13 (76.92%) women with OH, the appropriate LT4 dose coincided with the initial dose. Only 11% and 23% respectively required additional adjustments. Once the appropriate dose of LT4 was prescribed, the time at which euthyroidism (mean ± SD, weeks) was confirmed was similar in patients with SCH (6.06 ± 3.3) and OH (5.3 ± 1.8). There were no miscarriages or premature deliveries.
When hypothyroidism is newly discovered during pregnancy, we suggest initiating the treatment with the following LT4 doses: 1.20 μg/kg/day for SCH with TSH ≤ 4.2 mIU/L, 1.42 μg/kg/day with TSH > 4.2-10, and 2.33 μg/kg/day for OH. By taking this approach, patients will promptly attain the euthyroid state avoiding additional increments and, probably, obstetric risks.
最近的指南建议,在孕早期 TSH 目标值应≤2.5mIU/L,在随后的孕中期和孕晚期应≤3mIU/L。应尽快实现甲状腺功能正常,但关于初始左甲状腺素(LT4)剂量并没有明确的指示。我们的研究目的是确定适当的 LT4 剂量,以在妊娠期间新发现的亚临床甲状腺功能减退症(SCH)患者中使 TSH 水平正常化,并与基础 TSH 水平相关联。还将比较患有 SCH 的女性所需的 LT4 剂量与患有显性甲状腺功能减退症(OH)的孕妇所需的 LT4 剂量。
回顾性分析了 77 例在妊娠期间新诊断为甲状腺功能减退症的患者。患者被分为 1 组(n=64),患有 SCH;或 2 组(n=13),患有 OH。SCH 患者分为两组:1a 组血清 TSH>2.5(孕早期)或>3(孕中期或孕晚期)至 4.2mIU/L;和 1b 组 TSH 水平>4.21-10mIU/L。一旦诊断出甲状腺功能减退症,所有患者均给予 LT4 治疗。使 TSH 在孕早期达到≤2.5mIU/L 或在孕中期和孕晚期达到≤3mIU/L 的 LT4 剂量被认为是合适的剂量。
1 组和 2 组之间观察到 LT4 适当剂量(平均值±标准差,μg/kg/天)有显著差异(p<0.0001):1.31±0.36 与 2.33±0.59。1a 组患者需要的 LT4 剂量明显较低(p<0.014):1.20±0.39 与 1.42±0.31μg/kg/天。在 64 例 SCH 患者中的 57 例(89.06%)和 13 例 OH 患者中的 10 例(76.92%)中,适当的 LT4 剂量与初始剂量一致。分别只有 11%和 23%需要额外调整。一旦规定了适当的 LT4 剂量,SCH 患者(平均±SD,周)达到甲状腺功能正常的时间(6.06±3.3)与 OH 患者(5.3±1.8)相似。没有发生流产或早产。
当妊娠期间新发现甲状腺功能减退症时,我们建议开始治疗时给予以下 LT4 剂量:SCH 患者 TSH≤4.2mIU/L 时为 1.20μg/kg/天,TSH>4.2-10 时为 1.42μg/kg/天,OH 患者为 2.33μg/kg/天。采用这种方法,患者将迅速达到甲状腺功能正常状态,避免额外增加剂量,并可能避免产科风险。